- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00410514
A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi-center Study to Evaluate the Urodynamics and Safety of YM178 in Male Subjects With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
Przegląd badań
Status
Interwencja / Leczenie
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
British Columbia
-
Victoria, British Columbia, Kanada, V8T 5G1
-
Victoria, British Columbia, Kanada, V8V 3N1
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3A 1R9
-
-
New Brunswick
-
St John, New Brunswick, Kanada, E2L 378
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3H 3A7
-
-
Ontario
-
Kitchener, Ontario, Kanada, N2N 2B9
-
Toronto, Ontario, Kanada, M4N 3M5
-
-
Quebec
-
Chicoutimi, Quebec, Kanada
-
Chicoutimi, Quebec, Kanada, G7F 4A3
-
Montreal, Quebec, Kanada, H3T 1E2
-
Pointe-Claire, Quebec, Kanada, H9R 4S3
-
Sherbrooke, Quebec, Kanada, J1H 5N4
-
-
-
-
Arizona
-
Tuscon, Arizona, Stany Zjednoczone, 85712
-
-
California
-
Atherton, California, Stany Zjednoczone, 94027
-
Culver City, California, Stany Zjednoczone, 90232
-
Fresno, California, Stany Zjednoczone, 93720
-
San Diego, California, Stany Zjednoczone, 92103
-
Torrance, California, Stany Zjednoczone, 90505
-
-
Connecticut
-
Middlebury, Connecticut, Stany Zjednoczone, 06762
-
-
Florida
-
Tallahassee, Florida, Stany Zjednoczone, 32308
-
-
Iowa
-
Des Moines, Iowa, Stany Zjednoczone, 50309
-
-
Louisiana
-
Shreveport, Louisiana, Stany Zjednoczone, 71106
-
-
Massachusetts
-
Watertown, Massachusetts, Stany Zjednoczone, 02472
-
-
New York
-
Garden City, New York, Stany Zjednoczone, 11530
-
-
North Carolina
-
Winston Salem, North Carolina, Stany Zjednoczone, 27103
-
-
Ohio
-
Cincinnati, Ohio, Stany Zjednoczone, 45212
-
-
Virginia
-
Virginia Beach, Virginia, Stany Zjednoczone, 23454
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Men 45 years of age or older
- Documented bladder outlet obstruction
Exclusion Criteria:
- History of urinary retention
- Symptomatic and recurrent urinary tract infection (UTI)
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Potroić
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Komparator placebo: Placebo
Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.
|
doustny
|
Eksperymentalny: Mirabegron 50 mg
Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.
|
doustny
Inne nazwy:
|
Eksperymentalny: Mirabegron 100 mg
Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.
|
doustny
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Change From Baseline to End of Treatment in Maximum Flow Rate (Qmax)
Ramy czasowe: Baseline and Week 12
|
Maximum urinary flow rate (Qmax) was measured by the Investigator using cystometry and was sent to an independent central reading center for review and interpretation. Least squares means (LSM) were derived from an analysis of covariance (ANCOVA) model with the pooled study center and treatment as factors and the baseline value as a covariate. |
Baseline and Week 12
|
Change From Baseline to End of Treatment in Detrusor Pressure at Maximum Flow Rate (PdetQmax)
Ramy czasowe: Baseline and Week 12
|
Detrusor pressure at maximum urinary flow rate (PdetQmax) was measured by the Investigator using cystometry and was sent to an independent central reading center for review and interpretation. Least squares means (LSM) were derived from an analysis of covariance (ANCOVA) model with the pooled study center and treatment as factors and the baseline value as a covariate. |
Baseline and Week 12
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Change From Baseline to End of Treatment in Bladder Contractile Index (BCI)
Ramy czasowe: Baseline and Week 12
|
The Bladder Contractile Index (BCI) is a value used to measure the degree of contractility. BCI was calculated using the following formula: BCI = pdetQmax + 5Qmax. Strong contractility is a BCI > 150, normal contractility is a BCI of 100-150 and weak contractility is a BCI of < 100. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate. |
Baseline and Week 12
|
Change From Baseline to End of Treatment in Bladder Voiding Efficiency (BVE)
Ramy czasowe: Baseline and Week 12
|
Bladder Voiding Efficiency (BVE) is a product of bladder contractility against the urethral resistance and is measured according to the degree of bladder emptying. BVE is expressed as a percentage and is calculated using the formula: Bladder Voiding efficiency = (Voided volume x 100)/maximum cystometric capacity. A higher number indicates a higher voiding efficiency. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate. |
Baseline and Week 12
|
Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Postvoid Residual Volume (PVR)
Ramy czasowe: Baseline and Weeks 1, 4, 8 and 12
|
Healthy micturitions (urinations) result in complete emptying of the bladder. Post Void Residual (PVR) is the volume of urine retained after voiding and was assessed using abdominal ultrasound. An increasing PVR over time is an indicator of abnormal bladder function or detrusor decompensation. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate. |
Baseline and Weeks 1, 4, 8 and 12
|
Safety Assessed by Adverse Events (AEs), Electrocardiogram (ECG), Vital Signs, Physical Exam and Laboratory Tests
Ramy czasowe: From first dose to within 30 days after last dose of double blind study medication (up to 16 weeks).
|
Abnormal laboratory parameters, vital signs or ECG data were defined as AEs if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant.
A serious AE was an event resulting in death, persistent or significant disability/incapacity or congenital anomaly or birth defect, was life-threatening, required or prolonged hospitalization or was considered medically important.
AEs were assessed by the Investigator for intensity as mild, moderate or severe and for causal relationship to study drug.
|
From first dose to within 30 days after last dose of double blind study medication (up to 16 weeks).
|
Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in International Prostate Symptoms Score (IPSS) Total Score
Ramy czasowe: Baseline and Weeks 1, 4, 8 and 12
|
The IPSS is a validated global questionnaire used to assess the degree of "bother" from benign prostatic hyperplasia symptoms and is based on the answers to 7 questions concerning urinary symptoms. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The total score can therefore range from 0 to 35 (asymptomatic to very symptomatic). Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate. |
Baseline and Weeks 1, 4, 8 and 12
|
Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in International Prostate Symptoms Score (IPSS) Voiding Score
Ramy czasowe: Baseline and Weeks 1, 4, 8 and 12
|
The IPSS is a validated global questionnaire used to assess the degree of "bother" from benign prostatic hyperplasia symptoms based on the answers to 7 questions concerning urinary symptoms. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The voiding score is the sum of the responses to 4 questions relating to urination (incomplete emptying, intermittency, weak stream and straining) and ranges from 0 to 20 (asymptomatic to very symptomatic). Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate. |
Baseline and Weeks 1, 4, 8 and 12
|
Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in International Prostate Symptoms Score (IPSS) Storage Symptom Score
Ramy czasowe: Baseline and Weeks 1, 4, 8 and 12
|
The IPSS is a validated global questionnaire used to assess the degree of "bother" from benign prostatic hyperplasia symptoms based on the answers to 7 questions concerning urinary symptoms. Each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. The storage symptom score is the sum of the responses to 3 questions relating to storage symptoms (frequency, urgency and nocturia) and ranges from 0 to 15 (asymptomatic to very symptomatic). Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate. |
Baseline and Weeks 1, 4, 8 and 12
|
Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Patient Perception of Bladder Condition (PPBC)
Ramy czasowe: Baseline and Weeks 1, 4, 8 and 12
|
The patient perception of bladder condition (PPBC) asks participants to assess their bladder condition using a 6-point validated Likert scale which ranges from 1 (does not cause me any problems at all) to 6 (causes me many severe problems). Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate. |
Baseline and Weeks 1, 4, 8 and 12
|
Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Mean Number of Micturitions Per 24 Hours
Ramy czasowe: Baseline and Weeks 1, 4, 8 and 12
|
A micturition is any voluntary urination, excluding episodes of incontinence only. The mean number of micturitions per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate. |
Baseline and Weeks 1, 4, 8 and 12
|
Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Mean Number of Urgency Episodes With Urgency Severity ≥ 3 Per 24 Hours
Ramy czasowe: Baseline and Weeks 1, 4, 8 and 12
|
For each micturition and/or incontinence episode in the 3 days preceding the clinic visit, participants rated the degree of associated urgency (the sudden compelling desire to pass urine, which is difficult to defer) according to the following scale: 0: No Urgency, felt no need to empty my bladder but did so for another reason; 1: Mild Urgency, could postpone passing water for as long as necessary; 2: Moderate Urgency, could postpone passing water for a short while; 3: Severe Urgency, could not postpone passing water; 4: Urge Incontinence, leaked before reaching the toilet. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate. |
Baseline and Weeks 1, 4, 8 and 12
|
Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Mean Number of Incontinence Episodes Per 24 Hours
Ramy czasowe: Baseline and Weeks 1, 4, 8 and 12
|
The mean number of incontinence episodes (the involuntary leakage of urine) per 24 hours was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate. |
Baseline and Weeks 1, 4, 8 and 12
|
Change From Baseline to Weeks 1, 4, 8, 12 and End of Treatment in Mean Voided Volume Per Micturition
Ramy czasowe: Baseline and Weeks 1, 4, 8 and 12
|
The mean volume voided per micturition was calculated from data recorded by the participant in the micturition diary for the 3 days preceding each clinic visit. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate. |
Baseline and Weeks 1, 4, 8 and 12
|
Change From Baseline to Weeks 4, 8, 12 and End of Treatment in International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptom (ICIQ MLUTS) Total Symptom Score
Ramy czasowe: Baseline and Weeks 4, 8 and 12
|
Male lower urinary tract symptoms were assessed by the ICIQ MaleLUTS questionnaire which consists of 13 questions each on a 0-4 scale (larger scores correspond to worse conditions). The total symptom score ranges from 0 to 52. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate. |
Baseline and Weeks 4, 8 and 12
|
Change From Baseline to Weeks 4, 8, 12 and End of Treatment in International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptom (ICIQ MLUTS) Total Bother Score
Ramy czasowe: Baseline and Weeks 4, 8 and 12
|
The degree to which urinary symptoms bothered participants was assessed by the ICIQ MaleLUTS questionnaire which consists of 13 symptom bother questions each on a 0-10 scale (larger scores correspond to worse outcomes). The total bother score ranges from 0 to 130. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate. |
Baseline and Weeks 4, 8 and 12
|
Change From Baseline to Weeks 4, 8, 12 and End of Treatment in International Consultation on Incontinence Questionnaire - Lower Urinary Tract Symptom Quality of Life (ICIQ-LUTSqol) Symptom Score
Ramy czasowe: Baseline and Weeks 4, 8 and 12
|
Quality of life was assessed by the ICIQ-LUTSqol questionnaire which consists of 19 questions each on a 1-4 scale (larger scores correspond to less quality of life). The total symptom score ranges from 19 - 76. Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate. |
Baseline and Weeks 4, 8 and 12
|
Change From Baseline to Weeks 4, 8, 12 and End of Treatment in International Consultation on Incontinence Questionnaire - Lower Urinary Tract Symptom Quality of Life (ICIQ-LUTSqol) Overall Symptom Interference of Life Score
Ramy czasowe: Baseline and Weeks 4, 8 and 12
|
Participants were asked to rate how much their urinary symptoms interfered overall with their everyday life on a scale from 0 (not at all) to 10 (a great deal). Least squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate. |
Baseline and Weeks 4, 8 and 12
|
Współpracownicy i badacze
Sponsor
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby Urologiczne
- Choroby Pęcherza Moczowego
- Manifestacje urologiczne
- Choroby cewki moczowej
- Niedrożność cewki moczowej
- Objawy dolnych dróg moczowych
- Niedrożność szyi pęcherza moczowego
- Fizjologiczne skutki leków
- Środki adrenergiczne
- Agentów neuroprzekaźników
- Molekularne mechanizmy działania farmakologicznego
- Środki urologiczne
- Agoniści adrenergiczni
- Beta-agoniści adrenergiczni
- Agoniści receptora adrenergicznego beta-3
- Mirabegron
Inne numery identyfikacyjne badania
- 178-CL-060
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Placebo
-
SamA Pharmaceutical Co., LtdNieznanyOstre zapalenie oskrzeli | Ostra infekcja górnych dróg oddechowychRepublika Korei
-
National Institute on Drug Abuse (NIDA)ZakończonyUżywanie konopi indyjskichStany Zjednoczone
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyZakończonyMężczyźni z cukrzycą typu II (T2DM)Niemcy
-
West Penn Allegheny Health SystemZakończonyAstma | Alergiczny nieżyt nosaStany Zjednoczone
-
Heptares Therapeutics LimitedZakończonyFarmakokinetyka | Problemy z bezpieczeństwemZjednoczone Królestwo
-
Longeveron Inc.ZakończonyZespół niedorozwoju lewego sercaStany Zjednoczone
-
ItalfarmacoZakończonyDystrofia mięśniowa BeckeraHolandia, Włochy
-
Soroka University Medical CenterZakończony
-
Regado Biosciences, Inc.ZakończonyZdrowy ochotnikStany Zjednoczone